This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

New Milestones In Visius Surgical Theatre By Imris

Stocks in this article: IMIMRS

- University of Virginia Striding Ahead with Intraoperative Imaging Suite -

WINNIPEG, May 8, 2012 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM) ("IMRIS" or the "Company") today reported on the preliminary successes that the University of Virginia (UVA) has achieved in their VISIUS Surgical Theatre.   UVA clinicians have treated over 50 patients in their VISIUS Surgical Theatre since its opening, achieving two important milestones in the use of their new intraoperative imaging capabilities.

Scott Lim, MD, Director of Pediatric & Adult Congenital Cardiac Catheterization, performed the very first cardiac intervention in a VISIUS Surgical Theatre when he treated a six-year old patient with a right heart catheter diagnosis using the combination of MR and x-ray imaging modalities of the suite.  Dr. Lim stated: "We are very pleased with the system for cardiac procedures.  In this case, we were able to acquire MR images in the cath lab immediately before the procedure, which eliminated the complexities of patient scheduling and patient movement through hospital.  In addition, by fusing MR images with angiography, we eliminated contrast agent and reduced 99% of the radiation we typically use on these patients."

Jeff Elias, MD, Associate Professor of Neurological Surgery and Neurology and Director of Stereotactic and Functional Neurosurgery, is the first to have performed stereotactic procedures in the VISIUS Surgical Theatre.  Using the rotational angiographic capabilities of the bi-plane, Dr. Elias creates 3D anatomical images of the brain which are then fused with images generated by the intraoperative MR to enhance his visualization of the brain.  Dr. Elias commented: "The combination of imaging modalities in this suite is critical for procedures treating Parkinson's or Essential Tremor.  The capability to fuse MR and angiographic images in real time improves our ability to plan surgery and operate with precision without transporting the patient."

The VISIUS Surgical Theatre at UVA features two state-of-the-art operating rooms connected by a room used for diagnostic imaging, and a ceiling-mounted MR scanner that moves between all three rooms.    Mark Shaffrey, MD, Chair, Department of Neurosurgery, who championed the effort to implement intraoperative MR at UVA and performed the first neurosurgical procedure in the suite, is encouraged by the initial successes of the clinical team: "The VISIUS Surgical Theatre is allowing us to combine biplane angiography with intraoperative MR imaging for extremely targeted, image-guided treatment and for visualization of anatomy to see that our surgical objectives are achieved.  The result is simple - better surgical results for our patients."

About IMRIS

IMRIS (NASDAQ: IMRS; TSX: IM) is a global leader in providing image guided therapy solutions through its VISIUS Surgical Theatre - a revolutionary, multifunctional surgical environment that provides unmatched intraoperative vision to clinicians to assist in decision making and enhance precision in treatment. VISIUS Surgical Theatres serve the neurosurgical, cardiovascular and cerebrovascular markets and have been selected by leading medical institutions around the world.

SOURCE IMRIS Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,810.06 +91.06 0.51%
S&P 500 2,063.50 +10.75 0.52%
NASDAQ 4,712.97 +11.1030 0.24%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs